Full Press Release Details
ALX Oncology Announces First Patient Dosed in ASPEN-03, a Phase 2 Study of ALX148 in Combination with KEYTRUDA (pembrolizumab) for the Treatment of Patients with Advanced Head and Neck Squamous Cell Carcinoma.
ALXO
ALX Oncology Announces First Patient Dosed in ASPEN-03, a Phase 2 Study of ALX148 in Combination with KEYTRUDA (pembrolizumab) for the Treatment of Patients with Advanced Head and Neck Squamous Cell Carcinoma
Key Takeaway: ALX Oncology Announces First Patient Dosed in ASPEN-03, a Phase 2 Study of ALX148 in Combination with KEYTRUDA (pembrolizumab) for the Treatment of Patients with Advanced Head and Neck Squamous Cell Carcinoma